Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
Registration date period
Results ordered by trial registration date, descending.
  1. Randomized, open label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with hormone therapy driven by circulating DNA ESR1 mutation monitoring in estrogen receptor-positive, HER2-negative metastatic breast cancer patients PADA-1 (PAlbociclib and circulating tumor DNA for ESR1 mutation detection)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Unknown
    Source name:
    EU Clinical Trials Register

    Population: STEP 1 • To assess the global safety of the combination of palbociclib + endocrine therapy in the whole population of patients, throughout the study, including the potential sequential...

    Conditions:
    • HER-2 negative metastatic breast cancer
    Interventions:

    Unknown

  2. Investigation of the Value of ctDNA in Diagnosis, Treatment, and Surveillance of Surgically Resectable Colorectal Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    In this study, we aim to investigate the value of circulating tumor DNA (ctDNA) analysis in the diagnosis, treatment, and surveillance of patients with surgically resectable colorectal ...

    Conditions:
    • Rectal Cancer, Adenocarcinoma
    • Neoadjuvant Chemoradiation
    Interventions:
    • Radical resection
    • Capecitabine/oxaliplatin
    • no adjuvant chemotherapy
    • local resection
  3. Circulating Tumor Cells and Tumor DNA in HCC and NET

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    Background Treatment and control of cancer is associated with high costs, to patients in the form of side effects and discomfort during investigations, to society in the form of expensive...

    Conditions:
    • Carcinoma, hepatocellular
    • Neuroendocrine Tumors
    Interventions:
    • Lanreotide
    • EVEROLIMUS
    • SORAFENIB
    • Radiofrequency ablation (RFA) or surgery
  4. ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    The study aims to explore the prevalence of ALK/ROS1/MET mutations assessed with ctDNA samples in EGFR-wildtype NSCLC

    Conditions:
    • EGFR Wildtype
    • Non-small Cell Lung Cancer Metastatic
    • Non-small cell lung cancer, stage III
    • Adenocarcinoma of Lung
    Interventions:
    • ctDNA analysis
  5. Circulating Cell-free Tumor DNA(ctDNA) in Pancreatic Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA(ctDNA) can help early screening of pancreatic cancer recurrence or not. And we are also planning to...

    Conditions:
    • Pancreatic cancer
    Interventions:

    Unknown

  6. Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting...

    Conditions:
    • Lung Neoplasms
    • Carcinoma
    • non-small cell lung cancer
    Interventions:

    Unknown

  7. Circulating Tumoral DNA in Choroidal Melanoma (ctDNA MU)

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    Quantification and follow-up during 3 years of circulating tumoral DNA in patients with choroidal melanoma

    Conditions:
    • Choroidal Melanoma
    Interventions:
    • Blood sampling
  8. Use of ctDNA for Monitoring of Stage III Colorectal Cancer

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Recruiting
    Source name:
    ClinicalTrials.gov

    This observational study will evaluate circulating tumor DNA (ctDNA) as a prognostic marker and as a monitor of disease recurrence in stage III colorectal cancer (CRC).

    Conditions:
    • Stage III colorectal cancer
    Interventions:

    Unknown

  9. Identifying Genomic Mutations of Multiple Primary Lung Cancers by Circulating Tumor DNA

    Registration date:
    Status:
    Ongoing
    Recruitment status:
    Not recruiting
    Source name:
    ClinicalTrials.gov

    Targeted next generation sequencing (NGS) provides a promising method for diagnostic purposes by enabling the simultaneous detection of multiple gene mutations. This study is to evaluate...

    Conditions:
    • Thoracic Neoplasms
    • Carcinoma
    • non-small cell lung cancer
    Interventions:

    Unknown